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Abstract: Understanding HIV latent reservoirs in tissues is essential for the development of new
strategies targeting these sites for eradication. Here, we assessed the size of latent reservoirs and
the source of residual viruses in multiple lymphoid tissues of SIV-infected and fully suppressed
rhesus macaques of Chinese-origin (cRMs). Eight cRMs were infected with SIVmac251 and treated
with tenofovir and emtricitabine daily for 24 weeks initiated 4 weeks post-infection. Four of the
eight animals reached sustained full viral suppression with undetectable viremia. The levels of
cell-associated SIV DNA varied in peripheral blood mononuclear cells (PBMCs) and multiple
lymphoid tissues, but with higher levels in the mesenteric lymph nodes (MesLNs). The levels
of cell-associated SIV RNA also varied in different tissues. The higher frequency of viral RNA
detection in the MesLNs was also observed by in situ hybridization. Consistently, the infection unit
per million cells (IUPM) in the MesLNs was higher than in PBMCs and other tested lymphoid tissues
by quantitative viral outgrowth assay (QVOA). Furthermore, env gp120 from tissue SIV RNA was
amplified by single genome amplification. Phylogenetic analysis revealed diverse variants from
tissues parallel to the viral inoculum in all viral suppressed animals. These results demonstrate that
the latency and viral reservoirs in the lymphoid tissues still exist in aviremic macaques under full
suppressive therapy. Moreover, the size of viral latent reservoirs differs in various lymphoid tissues
with a relatively larger size in the MesLNs.
Keywords: simian immunodeficiency virus; rhesus macaques; lymph nodes; reservoir;
antiretroviral therapy
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1. Introduction
The viral latent reservoir remains a key barrier in HIV-1 eradication [1]. Although combination
antiretroviral therapy (cART) can effectively suppress the viral replication to undetectable levels in
peripheral blood, the current antiretroviral drugs are unable to eliminate cellular and tissue latent
reservoirs even with the earliest cART during hyperacute HIV infection [2]. Once cART is discontinued,
viral productive infections quickly rebound within a few weeks from latent reservoirs in HIV and
SIV infection. The exact sources of viral rebound have not been identified [3,4]. Lymph nodes (LNs),
the spleen, gut-associated lymphoid tissues, the reproductive system, and the central nervous system
are proposed to account for viral persistence [5]. One recent study showed that the B cell follicles of
lymph nodes harbor productive viral replication in elite SIV-controlling macaques due to less access
by SIV-specific cytotoxic T cells [6]. HIV also persists in follicular dendritic cells by trapping viable
virions on their surface and in follicular helper CD4+ T cells inside the germinal center of the LNs in
HIV-infected patients with suppressive cART [7,8] or in the lymphoid tissues in aviremic patients on
cART [9], indicating that the low-level ongoing virus replication may be another source of plasma
virus rebound after cessation of ART.
To identify and characterize cellular and tissue latent reservoirs or determine whether there
is an ongoing low-level replication in lymphoid tissues on suppressive ART, multiple methods
have to be used to corroborate each other, because different assays such as PCR-based, quantitative
viral outgrowth assay (QVOA), and in situ hybridization have different advantages and drawbacks.
However, the combination of these methods has not often been used in determining whether lymph
nodes harbor replication-competent viruses and whether there is ongoing active replication in tissues
under suppressive cART despite an undetectable viral load in peripheral blood. Thus far, by either
the assays of PCR-based or in situ hybridization, lymphoid tissues, and lymph nodes in particular,
have been found to contain high viral DNA loads [10,11].
Used in combination, the nucleoside reverse transcriptase inhibitors (NRTI), tenofovir and
emtricitabine, are still the basis of antiretroviral drugs in use with integrase or proteinase inhibitors
for treating HIV infection. Tenofovir and emtricitabine have also been used on rhesus macaques
of Chinese-origin (cRMs) for investigating latent reservoirs in the CNS [12] and mucosal immune
responses, where ~ 60% of animals can reach full viral suppression in peripheral blood when only
these two drugs were available for treatment [13]. It is relatively easier and quicker to suppress plasma
viral loads (pVL) in SIV infection in cRMs to undetectable levels by cART [14,15], as compared with
SIV infection in Indian rhesus macaques. This two-drug combination therapy in cRMs could suppress
plasma viral load to undetectable levels for latency studies [13].
In this study, we treated SIVmac251-infected cRMs with tenofovir and emtricitabine to examine
the size and the distribution of SIV latent reservoir(s) in lymphoid tissues. Four of the eight animals
reached sustained undetectable plasma viral loads on ART. At the end of ART, cell-associated viral
DNA was detected in PBMCs and all the lymphoid tissues examined (axillary, inguinal, mesenteric
lymph nodes and spleen). Cell-associated viral RNA was also detected in the lymphoid tissues
examined as above but not in PBMCs by qRT-PCR. The presence of SIV RNA+ cells in the mesenteric
lymph node tissues was confirmed by using in situ hybridization, indicating that there were persistent
viral reservoirs in lymphoid tissues despite aviremia. Furthermore, QVOA revealed that different
lymphoid tissues contained replication-competent viruses, of which the mesenteric lymph node tissues
had the highest number of infection units. In addition, the viral variants isolated in the lymphoid
tissues did not show specific compartmentalization by phylogenetic analysis but were similar in
diversity to the swarm virus in the inoculum. Our data demonstrate that the mesenteric lymph nodes
are likely to be one of the sources of viral reservoirs with possible continuous active viral replication.
Although it leads to sustained suppression of peripheral viremia by the two reverse transcriptase
inhibitors (RTi), a larger group of animals with earlier and longer treatment over 6 months and a
novel antiretroviral regimen can be tested in the SIV/cRM/cART model for further reduction of
these reservoirs.
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2. Materials and Methods
2.1. Animals and Virus Inoculation
Eight rhesus macaques of Chinese-origin (Macaca mulatta) were studied. The animals were housed
at the Tulane National Primate Research Center (TNPRC) and maintained in accordance with the
standards of the American Association for Accreditation of Laboratory Animal Care and the “Guide
for the Care and Use of Laboratory Animals” prepared by the National Research Council. The protocol
of all studies was approved by the Tulane Institutional Animal Care and Use Committee (IACUC,
P0121R-2015). The animals were sero-negative for SIV, simian D retrovirus and simian T-cell leukemia
virus prior to SIV inoculation. The animals were inoculated intravenously with 100 TCID50 of SIV
grown in culture from SIVmac251.
2.2. Antiretroviral Therapy
Beginning 4 weeks post-infection, each animal received the reverse transcriptase inhibitors
(R)-9-(2-phosphonylmethoxyypropyl) adenine (PMPA, tenofovir; 20 mg/kg) and beta-2′,3′ dideoxy-3′-
thia-5-fluorocytindine (FTC, emtricitabine; 40 mg/kg) daily by subcutaneous injection. ART was
continued through the end of the study for 24 weeks. The animals were then euthanized and necropsied
for extensive tissue collection for the reservoir evaluation. Tenofovir and emtricitabine were generously
provided by Gilead Sciences, Inc. (Foster City, CA, USA) via Material Transfer Agreements.
2.3. Quantification of Viral RNA in Plasma
The blood samples were collected in ethylenediamine tetraacetic acid (EDTA)-treated tubes and
the plasma was separated from whole blood and stored at −80 ◦C until use. The viral RNA (vRNA)
was extracted from the plasma using the high pure viral RNA kit (Roche; Indianapolis, IN, USA).
The SIV plasma viral loads (pVLs) were quantified by real-time quantitative PCR (qPCR) assay by the
Pathogen Detection and Quantification Core of Tulane National Primate Research Center as described
elsewhere [16] using the primers and probes for conserved gag region of SIVmac239 and SIVmac251.
2.4. Quantification of Cell-Associated SIV DNA and RNA from Blood and Lymphoid Tissues
The RNA from peripheral blood mononuclear cells (PBMCs) and lymphocytes obtained from the
lymph nodes and spleen during the necropsies was isolated with TRIzol® Reagent (Thermo fisher
scientific, Waltham, MA, USA) according to the manufacturer’s protocol with slight modifications.
The sample was separated with chloroform and the aqueous phase was treated with isopropanol to
precipitate the RNA; the interphase was used to precipitate the DNA. The TaqMan Gene Expression
Master Mix (LifeTechnologies, Inc., Carlsbad, CA, USA) was used in the qRT-PCR reaction. The levels
of the cell-associated (CA) SIV DNA and CA SIV RNA viral loads were determined using methods
described in detail elsewhere [14].
2.5. SIV RNA Detection in Lymphoid Tissues Using in Situ Hybridization
Axillary lymph nodes (AxLNs), mesenteric lymph nodes (MesLNs), and spleen tissues were
collected at necropsy, fixed in Z-fix and embedded in paraffin. Six-micrometer-thick sections of tissue
were cut and mounted on charged glass slides (Fisher Scientific, Waltham, MA, USA). Isotope 35S
labeled sense or the antisense riboprobes of SIV were used as described previously [17]. The slides
were exposed for 2 weeks.
2.6. Isolation and Purification of Resting CD4+ T Cells from Blood and Tissues
PBMCs were purified from whole blood via Hypaque–Ficoll gradient centrifugation. The CD4+ T
cells from PBMCs as well as lymphocytes isolated from LNs and the spleen were negatively selected
to remove CD8+ T cells, B cells, monocytes, NK cells, and granulocytes cells using a cocktail of
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biotin-conjugated antibodies and anti-biotin micro magnetic beads using a non-human primate
microbeads CD4+ T cell isolation kit, (Milltenyi Biotech, Auburn, CA, USA). The purified CD4+
T cells were further separated by non-human primate microbeads, anti-CD25 and anti-HLA-DR
antibodies for resting CD4+ T cells. The resulting resting CD4+ T-cell population generally reached
>95% purity.
2.7. Quantitative Viral Outgrowth Assay (QVOA)
Highly purified resting CD4+ T cells were activated in the presence of 0.5 µg of PHA/mL to
stimulate the virus production from latently infected cells. The purified resting cells were carefully
counted and suspended to 1× 106 cells/mL in PHA containing media. The purified cells were cultured
in duplicate using 5-fold limiting dilution, ranging from 1 × 106 to 3.2 × 102 cells/mL, respectively.
On day 2, PHA was removed with medium containing IL-2. The cells were co-cultured with 1 × 105
CEMx174 for two weeks. The CEMx174 cells served to expand the virus released from infected cells
as previously described [18]. The culture supernatant was collected weekly, and fresh medium was
added to the culture. Culture supernatants were stored at −80 ◦C in 1.5-mL aliquots. The frequency
of cells harboring replication-competent viruses was determined by limiting dilution assay statistics
and expressed as the infectious units per million (IUPM) that was calculated using the IUPMStats v1.0
infection frequency calculator (available online: http://silicianolab.johnshopkins.edu) [19].
2.8. SIV env Sequence Analysis
Total RNA was extracted from PBMCs at different time points, lymphocytes from LNs, and spleen
tissues at necropsies. The extracted RNA was reverse transcribed into cDNA using the SuperScript
III reverse transcriptase enzyme kit (Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s protocol. cDNA was then used for single genome amplification (SGA). Platinum PCR
SuperMix High Fidelity kit (Life Technologies) was used for nested PCR following the manufacturer’s
protocol. The initial PCR cycles (1st round) were carried out using the following primers: 1st round
(Fwd: 5′-CTA TAA TAG ACA TGG AGA CAC CCT TG-3′; Rev: 5′-CTT CTT GCA CTG TAA TAA
ATC CCT TCC-3′) and 2nd round (Fwd: 5′-ATG CAA CCA CTC CAG AAT CGG C-3′; Rev: 5′-GGA
ACT CTC CTC TGC AAT TTG TCC-3′). Both rounds were amplified with the same cycling conditions:
94 ◦C for 2 min then 40 cycles of 94 ◦C for 30 s, 55 ◦C for 30 s, and 72 ◦C for 1 min. The size of the
resulting product was ~1500 base pairs. The PCR product was purified using the DNA and PCR clean
kit (Qiagen DNA purification kit, Hilden, Germany) according to the manufacturer’s protocol and
used for sequencing. The raw sequences were assembled using Sequencher 5.4.1 sequencing software
(Gene Codes Corporation, Ann Arbor, MI, USA). All assembled sequences were manually corrected
for individual ambiguous nucleotide errors and to eliminate any multiple templates. The SIV env
sequences were aligned with SIVmac239 and SIVmac251 as reference sequences. The sequences of the
KC522 series of SIVmac251 inoculum were also included in the analysis [20]. Molecular evolutionary
genetics analysis (MEGA) version 7.0 and the maximum likelihood (ML) method were used for the
generation of phylogenetic tree analysis [21].
2.9. Nucleotide Sequence Accession Numbers
Viral env sequences were deposited in GenBank under accession numbers MH745243-MH745367.
3. Results
3.1. Dynamics of SIV Plasma Viral Load during SIV Infection and Antiretroviral Therapy
Eight cRMs were infected with SIVmac251. Viremia peaked at 2 weeks post-infection to the
median of 8.5 × 106 copies/mL (ranging from 2.7 × 106–6 × 107 copies/mL) with the highest pVL
in animal EP22. By the time of the initiation of ART at week 4 post-infection, the median pVL was
reduced to 1 × 106 copies/mL (ranging from 1.3 × 105–2 × 107 copies/mL). ART was administered
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daily for 24 weeks (Figure 1). During ART, six animals reached undetectable plasma viral loads (pVL)
at different time points, while two of them (EP20 and GN75) had detectable pVL again by the end of
ART. The remaining four animals, EP22, EP49, GH09 and JH54, maintained undetectable levels until
the time of euthanasia. Two animals, CN05 and HE32, had decreased viral loads in the 1st month of
ART but maintained levels of 104–105 copies/mL similar to that of untreated animals as previously
observed [13], indicating mild or no response to ART.
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Figure 1. Dynamics of the SIV RNA load in plasma during SIV infection and combination antiretroviral
therapy (ART) in Chinese-origin rhesus macaques. ART was initiated at week 4 post-SIV infection and
continued for 24 weeks. The arrow indicates the period of continuous ART. The dashed line shows
detection of the limitation (41 copies/mL). * time of euthanasia of the four animals with undetectable
plasma viral loads.
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Figure 2. Levels of cell-associated SIV DNA (A) and RNA (B) in blood, axillary lymph nodes (AxiLNs),
inguinal lymph nodes (IngLNs), mesenteric lymph nodes (MesLNs) and the spleen at the end of
6 months of ART in four animals with full viral suppression in peripheral blood. The dotted line
indicates the limit of detection.
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3.3. Cell-Associated SIV RNA in Blood, Peripheral LNs, Mesenteric LNs and the Spleen
To determine whether there is active SIV replication in lymphoid tissues, the CA SIV RNA levels
were quantified using qRT-PCR. SIV vRNAs were detectable in variant tissues from all four aviremic
animals. EP22 showed the highest SIV RNA levels in IngLNs. EP49 had detectable CA SIV RNA levels
in AxLNs and IngLNs. GH09 had detectable CA SIV RNA levels in all the LNs as well as in the spleen,
while CA SIV RNAs were only detected in the spleen of JH54. Interestingly, all four animals had no
detectable CA SIV RNA levels in PBMCs, indicating the effectiveness of the ART on peripheral blood
(Figure 2B).
3.4. SIV RNA+ Cells Were Detected in the Lymph Node Tissues of Aviremic Animals by in Situ Hybridization
To validate the qRT-PCR results, isotope 35S labeled anti-sense riboprobe in situ hybridization
(ISH) was used for vRNA+ cells detection in AxLNs, MesLNs, and spleen tissues. SIV RNA+ cells were
readily detected in the MesLNs and spleen tissues in all four aviremic animals on suppressive ART,
with higher frequency in the MesLNs than spleen tissues (Figure 3 and Figure S1), while SIV RNA+
cells were rarely detected with a few positive cells in entire tissue sections in AxLNs and in the spleen
(Figure S1). The isotope 35S labeled sense riboprobe was used as a negative control and we did not
detect signals (Figure S2). Additionally, the anti-sense riboprobe hybridized to SIV-uninfected macaque
MesLN tissues was used as a negative control and we did not detect any signal either (Figure S2).
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3.5. The Size of Viral Latent Reservoir Was Higher in Mesenteric LN Than Other Tested Tissues
We further used the viral outgrowth assay to evaluate the size of viral reservoirs of the
replication-competent viruses in the collected tissues. When compared with blood, spleen and
peripheral LNs, MesLNs had the largest sized reservoirs with the range of 1–4.2 IUPM in resting CD4+
T cells by the end of ART in EP22, GH09 and JH54 except EP49 which had low IUPM. It was noteworthy
that MesLNs were the only tissues that showed detectable IUPM in EP49 (Figure 4). Although the
levels in each individual had different absolute numbers, this result was concordant with the findings
by molecular assays.
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3.6. Viral Variants in Different Tissues
To assess SIV variants distribution in different compartments including blood, LNs and spleen,
we analyzed SIV env gp120 sequences using the single genome amplification (SGA) of viral RNA
and determined the phylogenetic relationship between the blood and lymphoid tissues. Due to the
undetectable plasma viral RNA, virion gp120 RNA sequences were not available in the plasma and
PBMCs of all four fully suppressed animals and some lymphoid tissues with an extremely low level of
viral RNA at the end of ART when the animals were euthanized. Therefore, we sequenced SIV env
gp120 in PBMCs at the peak (day 14) and day 30 post-SIV infection and also from the lymphocytes of
the AxLNs, IngLNs, MesLNs and spleen collected at necropsies when the PCR results were positive.
We obtained SIV env gp120 sequences from EP22 from all the lymph nodes at necropsy but not
from the spleen, whose sequences had no significant compartmentalization clusters from PBMCs at day
14, day 30 p.i. and all tissues during suppressive ART (Figure 5A). For animal EP49, we obtained only
two isolates from the IngLNs from 48 reactions of the SGA amplification, and no positives were found
in the PBMCs, AxLNs, MesLNs and spleen at the end of ART (Figure 5B). Similarly, we recovered one
isolate from the AxLNs and four isolates from the IngLNs in GH09 (Figure 5C). For JH54, we isolated
three variants from each tissue of the IngLNs and MesLNs without positives in the AxLNs and spleen
(Figure 5D). In each animal, the isolates from the different tissues were not significantly different from
those obtained from PBMCs at day 14 and day 30 post-infection before ART. The isolates were also not
different from the Tulane SIVmac251 virus stock lineages of KC522 series [20].
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Figure 5. Phylogenetic trees of SIV env gp120 sequences obtained from viral RNA from multiple
lymphoid tissues from the four animals with an undetectable plasma viral load during therapy.
Each tree represents each animal (A: EP22, B: EP49, C: GH09 and D: JH54). The tree scale bar indicates
the number of substitutions per site. Green circle: PBMC at day 14 post-infection; Solid round circle:
PBMC at day 30 post-infection; Red triangle: Axillary lymph node (AxLN); Inverted purple triangle:
Inguinal lymph node (IngLN); Blue triangle: Mesenteric lymph node (MesLN). The sequences of the
KC522 series of the SIVmac251 stocks [21}, SIVmac239 and SIVmac251, were obtained from GenBank
for comparison.
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4. Discussion
The establishment of a non-human primate model of HIV latency is essential for studies of viral
tissue reservoirs. Here, with the availability of tenofovir and emtricitabine generously provided
by Gilead, we treated eight cRMs and half of them reached full viral suppression with a sustained
undetectable plasma viral load. The latency status in four of these cRMs allowed us to study the size,
viral diversity, location and distribution of viral latent reservoirs or potential low-level replication
in different lymphoid tissues. Although it has been demonstrated that lymph nodes have the most
latently infected memory CD4+ T cells among tissue reservoirs in HIV-1-infected individuals and
SIV-infected macaques on fully suppressive cART, we found that the viral reservoir distribution in
different lymphoid tissues were at different levels in this SIV/cRM/ART model, parallel to other
SIV-susceptible NHP models, making it serve as an equally important model for HIV persistence and
cure research.
Molecular-based assays have been widely used to evaluate viral persistence in HIV-1 basic
research and clinical settings. The total HIV-1 DNA is a valuable marker reflecting HIV persistence
as this contains all forms of residual HIV in blood and tissues that contribute to viral production,
HIV pathogenesis and immune activation [22,23]. Cell-associated HIV-1 RNA may be able to
generate mRNAs and proteins that play a role in pathogenesis even though it may not contain
replication-competent viruses. These parameters are also frequently used in the NHP model. In
this study, we found that the levels of CA SIV DNA in tissues were measurable, indicating that
viral reservoirs exist in all of the tested tissues with the highest in the MesLNs. These results are
consistent with findings from other groups, which showed the highest levels of SIVgag RNA in the
MesLNs among tested lymphoid tissues in RT-SHIV-infected rhesus macaques on ART [24], and the
highest vRNA levels in both superior and inferior MesLNs [10]. Moreover, using in situ hybridization,
we showed consistent results that the MesLNs had detectable SIV RNA. Furthermore, by using the gold
standard QVOA, we confirmed that that the viruses harbored in the MesLNs are replication-competent.
Thus, by using PCR-based assays, in situ hybridization technology and gold standard cell culture
QVOA, we found that mesenteric lymph nodes harbored the most replication-competent viruses
compared to other peripheral LNs and spleen.
The size or level of the viral reservoir depends on the time of initiation of cART, the length of the
treatment period, the combination of different categories of antiretroviral drugs, individual biological
responses and other factors. Currently, there are three possible mechanisms of viral persistence and
reservoirs under suppressive cART, (1) long-live resting memory CD4+ T cells [25–27], possible tissue
macrophages [28–31] and other cell types [7,32]; (2) the clonal expansion of CD4+ T cells [33–36];
and (3) extremely low levels of ongoing productive replication or active reservoir. The latter possible
mechanism is still controversial with both evidence for [9,37–39] and against [40,41] it. It is well
understood that peripheral blood reservoirs do not reflect the status in different tissues. Conceivably,
undetectable viral loads in circulating blood do not mean that there are no viruses anywhere, because
the limit of detection is above zero. This is also because antiretroviral drugs cannot penetrate all body
sites equally with the existence of sanctuary sites.
Although we did not test tenofovir (TFV) and emtricitabine (FTC) concentrations in the LNs
and spleen, it has been shown that the average concentrations of TFV-diphosphate were 80% lower
and those of FTC-triphosphate were 66% lower in lymph nodes compared to those of PBMCs [38].
Therefore, productive replication is unexcluded in the LNs, particularly in the MesLNs. Since MesLNs
play a pivotal role in the center of immune anatomy [42], the observed high levels of SIV RNA in the
MesLNs are likely due to their particular sites and functions, which may deliver microbial translocation
from leaking gut with constant activation of SIV target cells.
The analysis of viral compartmentalization and evolution can provide valuable information on
whether there is productive viral replication under suppressive cART. Observing viral evolution would
clearly indicate active viral replication. However, it is extremely difficult to prove whether there is
ongoing evolution and replication under cART. Within HIV-infected humans, the extreme low levels
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of viral loads due to effective cART therapy usually result in difficulty when it comes to assessing
virus evolution. By the time that the treatment is started, there is already considerable diversity in the
virus population, thus it is very challenging to analyze any further viral evolution as small populations
cause much slower evolution. However, the lack of evidence of viral evolution does not mean that
viral replication production is not happening.
In this study, viral isolates were closely clustered with the TNPRC virus stock SIVmac251 such
as the KC522171-PM series that were sequenced in a previous study [20]. The inoculum had some
diversity as a swarm virus, as do most SIV stocks that are used for vaccines or other studies. There were
not any detectable tissue-specific lineages from the phylogenetic analysis. Almost all of the variability
was in one small region in the V1V2 loop as commonly seen for the SIVmac viruses, SIVsm and HIV-2,
in which the V1–V2 region is far more variable than in other regions. These viruses evolve differently
in the envelope than HIV-1 and other viruses. However, the small differences in our sequences were not
significant, and there had not been much evolution from the inoculum. Our results were consistent
with observations by others that no viral evolution was found in the LNs of SIVmac-infected macaques
on cART [43]. Again, if the virus is fairly well suppressed by cART, it might be unable to considerably
evolve. Significant evolution is expected more in untreated animals; for treated animals and elite
controllers, it is only expected over many years of infection [44,45].
Overall, the phylogenetic tree analysis did not demonstrate compartmentalization within the
same animal, indicating that the viruses in the LNs isolated at 24 weeks of ART were possibly derived
from variants which existed before ART started. It is also likely that 24 weeks of ART with only two
RTi were not effective enough to fully suppress the extremely low level of virus replication in tissues.
Since we did not have longitudinal samples from the same tissue, we were unable to directly address
the viral evolution issue using only this assay. However, in combination with the results from QVOA,
the production of residual viruses was likely from the MesLNs.
5. Conclusions
Together, we found that SIV-infected cRMs with full viral suppression in blood can be used
for SIV latency studies. Lymphoid tissues, particularly MesLNs, are viral tissue reservoirs of latent
infection without the exclusion of possibly extremely low ongoing viral production. Treatment periods
lasting longer than 6 months are likely needed for full suppression in tissues even if blood viremia is
consistently undetectable. Since the local microenvironment of the lymphoid tissues may contribute to
the uneven viral distribution, when evaluating viral reservoirs, multiple tissues need to be examined.
In addition, given that the sample size in this study is relatively small, we expect that future studies
with larger groups of animals receiving a potent triple-drug regimen for longer treatment will reduce
the size of the reservoirs in the MesLNs and other lymphoid tissues. Multiple methods, in combination
with PCR-based, in situ, and cell culture assays, may be needed to determine the effectiveness of new
approaches for SIV and HIV eradication.
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